7Pregnancy and autoimmune diseases
Section snippets
Fertility
There is no evidence that the disease SLE or any of the inflammatory arthritides, such as rheumatoid arthritis or spondyloarthropathy, affect fertility. In the past, there was concern that systemic sclerosis and anti-phospholipid antibody syndrome were associated with reduced fertility, but this has not been supported by more recent studies.1., 2. There have been no studies looking at fertility in the vasculitides, which more often affect women after the reproductive period.
The main risk
Systemic lupus erythematosus
The most studied autoimmune disease with respect to pregnancy is SLE. In the past, there was considerable concern that lupus was aggravated by oestrogens, especially in pregnancy. In recent years, there has been increasing interest in the role of prolactin as there is some evidence that prolactin is associated with pregnancy-related and postpartum flares.4 Data over the past 10 years have, however, shown that the risk of lupus flare is not as great as many people used to think and that flares,
Risk of autoimmune diseases being transmitted from mother to fetus
Maternal transmission of IgG antibodies to the fetus usually occurs between weeks 16 and 3242, but an autoimmune condition in the neonate may not be diagnosed until after delivery. The best-recognized condition is neonatal lupus syndrome due to the transmission of anti-Ro and/or anti-La antibodies to the fetus from a mother with lupus, primary Sjögren's syndrome or an undifferentiated connective tissue disease. There have been three reports of neonatal cutaneous vasculitis in infants born to
Effect of autoimmune diseases on fetal outcome
The two main determinants of fetal outcome in patients with autoimmune diseases are the degree of active disease at conception and the presence of anti-phospholipid antibodies. The two main outcomes are fetal loss and premature delivery. The term ‘fetal loss’ includes spontaneous abortions under 10 weeks, miscarriages between 10 and 24 weeks, and stillbirths from 24 weeks onwards.
Use of drugs in pregnancy and breast-feeding
The use of analgesic, anti-rheumatic and immunosuppressive therapy in pregnant patients with rheumatoid arthritis, lupus and vasculitis is summarised in Table 2, Table 3, Table 4. These tables also address the advisability of breast-feeding while taking these drugs.
Summary
Pregnancy in autoimmune conditions requires close co-operation between the physicians and obstetricians caring for the mother and fetus. Most maternal conditions improve in pregnancy if the disease is well controlled at the time of conception, but the disease may appear for the first time in pregnancy. Appropriate drug use to keep autoimmune disease suppressed and to reduce the risk of co-morbid complications, especially hypertension and thrombosis is important. For patients with
References (80)
- et al.
Antiphospholipid syndrome: obstetric diagnosis, management, and controversies
Obstetrics and Gynecology
(2003) Pregnancy in SLE
Baillière's Clinical Rheumatology
(1998)- et al.
Systemic lupus erythematosus flares during pregnancy
Rheumatic Disease Clinics of North America
(1997) Pregnancy in SLE
Baillière's Clinical Rheumatology
(1998)- et al.
Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia
American Journal of Medicine
(1986) - et al.
Primary anti-phospholipid antibody syndrome (APS): current concepts
Surveys in Ophthalmology
(2002) - et al.
Management of venous thromboembolism during pregnancy
Journal of Thrombosis and Haemostasis
(2003) - et al.
Management of pregnancy in antiphospholipid syndrome
Rheumatic Disease Clinics of North America
(2001) - et al.
Immunology of pregnancy–pregnancy as a remission inducing agent in rheumatoid arthritis
Transplant Immunology
(2002) - et al.
Spondyloarthritides in females
Baillière's Clinical Rheumatology
(1998)